Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER 11INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Lymphoid 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Influenza Vaccines × Other hematologic neoplasm × Clear all
NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡